<DOC>
	<DOCNO>NCT02346253</DOCNO>
	<brief_summary>This phase I/II trial study side effect well high-dose brachytherapy work treat patient prostate cancer spread part body . Brachytherapy type radiation therapy radioactive material seal needle , seed , wire , catheter place directly near tumor may better treatment patient prostate cancer .</brief_summary>
	<brief_title>High-Dose Brachytherapy Treating Patients With Prostate Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To estimate rate acute ( within six month high-dose rate [ HDR ] completion ) grade &gt; = 2 genitourinary ( GU ) toxicity follow high-dose-rate ( HDR ) brachytherapy ( BT ) monotherapy newly diagnose prostate cancer use National Cancer Institute 's Common Terminology Criteria Adverse Events , version 3 ( CTCAE v3.0 ) . SECONDARY OBJECTIVES : I . To estimate proportion men prostate-specific antigen ( PSA ) nadir one year ( nPSA12 ) &lt; 2 ng/mL . II . To estimate rate freedom biochemical failure 5 year ( FFBF ) . III . To evaluate patient-reported quality life via 32-item Expanded Prostate Cancer Index Composite ( EPIC ) . IV . To assess cost-effectiveness HDR BT monotherapy prostate cancer use 6-item European Quality Life 5-Dimensions ( EQ-5D ) . V. To explore pre-treatment clinical risk factor optimize patient selection HDR BT monotherapy prostate cancer . VI . To compare acute late ( &gt; 6 month HDR completion ) GU gastrointestinal ( GI ) grade &gt; = 2 toxicity use CTCAE v3.0 v4.0 . VII . To explore dosimetric predictor toxicity . OUTLINE : Patients undergo high-dose-rate brachytherapy 2 fraction . Patients may receive androgen deprivation therapy ( ADT ) comprise bicalutamide orally ( PO ) daily ( QD ) . Patients may also receive luteinizing hormone-releasing hormone ( LHRH ) agonist therapy comprise leuprolide acetate intramuscularly ( IM ) subcutaneously ( SC ) , goserelin acetate SC , triptorelin pamoate IM , degarelix SC 4-6 month ( intermediate-risk patient receive ADT ) 6-36 month ( high-risk patient ) discretion treat physician . After completion study treatment , patient follow 3 , 6 , 9 , 12 month , yearly 5 year .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<mesh_term>Triptorelin Pamoate</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<mesh_term>Bicalutamide</mesh_term>
	<criteria>Documented pathologic confirmation prostate adenocarcinoma Clinical Tclassification T13 PSA &lt; 150 ng/mL Gleason score 610 No evidence distant metastasis base history/physical examination ( include least digital rectal examination prostate assessment abdomen skeletal system ) Clinically negative lymph node establish abdominopelvic CT , 90 day prior toregistration ; CT clinical classification &gt; T3 ( contrast renal function acceptable ; noncontrast CT permit patient candidate contrast ) magnetic resonance imaging ( MRI ) , nodal sampling , dissection . Patients lymph node equivocal questionable image eligible node &lt; 1 cm short axis . No evidence bone metastasis ( M0 ) bone scan ( sodium fluoride [ NaF ] positron emission tomography [ PET ] /CT acceptable substitute ) perform 120 day prior registration ; equivocal bone scan finding allow plain film and/or MRI negative definite metastasis American Urological Association Symptom Index ( AUA SI ) = &lt; 15 No prior transurethral resection prostate ( TURP ) Clinical T4 disease N1 patient ineligible , pelvic lymph node &gt; = 1 cm short axis diameter , define pathologically enlarge per Response Evaluation Criteria Solid Tumors ( RECIST ) 1.1 , CT MRI abdomen pelvis , unless enlarge lymph node negative sample PSA &gt; = 150 ng/mL AUA SI &gt; 15 History radical prostatectomy , external beam radiotherapy ( EBRT ) , BT prostate cancer Prior invasive malignancy ( except nonmelanoma skin cancer ) , unless diseasefree least 3 year ; patient history pelvic hematologic malignancy eligible , regardless diseasefree interval Previous chemotherapy malignancy , give within three year registration Past history investigational agent History rectal surgery History rectal fistula History inflammatory bowel disease Severe , active comorbidity , define follow : Unstable angina and/or congestive heart failure require hospitalization within last six month Transmural myocardial infarction within last six month Acute bacterial fungal infection require intravenous antibiotic time registration Chronic obstructive pulmonary disease exacerbation respiratory illness require hospitalization preclude study therapy time registration Severe hepatic disease , define diagnosis ChildPugh class B C liver disease Human immunodeficiency virus ( HIV ) positivity cluster differentiation ( CD ) 4 count &lt; 200 cells/microliter ; note HIVpositive patient eligible , provide treatment highly active antiretroviral therapy ( HAART ) CD4 count &gt; = 200 cells/microliter 30 day prior registration ; note also HIV test require eligibility protocol Endstage renal disease ( i.e. , patient require advise undergo dialysis ) Prior allergic reaction study drug ( ) involve protocol</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>